TY - JOUR T1 - Sclerostin and Antisclerostin Antibody Serum Levels Predict the Presence of Axial Spondyloarthritis in Patients with Inflammatory Bowel Disease JF - The Journal of Rheumatology JO - J Rheumatol SP - 630 LP - 637 DO - 10.3899/jrheum.170833 VL - 45 IS - 5 AU - Michele Maria Luchetti AU - Francesco Ciccia AU - Chiara Avellini AU - Devis Benfaremo AU - Giuliana Guggino AU - Alessia Farinelli AU - Monia Ciferri AU - Matteo Rossini AU - Silvia Svegliati AU - Tatiana Spadoni AU - Laura Bolognini AU - Giammarco Fava AU - Piergiorgio Mosca AU - Rosaria Gesuita AU - Edlira Skrami AU - Giovanni Triolo AU - Armando Gabrielli Y1 - 2018/05/01 UR - http://www.jrheum.org/content/45/5/630.abstract N2 - Objective. The early diagnosis of inflammatory bowel disease (IBD)-associated spondyloarthritis (SpA/IBD) in patients affected by IBD represents a major topic in clinical practice; in particular, to date there are no available serum biomarkers revealing the presence of joint inflammation in these patients. Sclerostin (SOST), an antagonist of the Wnt/β-catenin pathway, and antisclerostin-immunoglobulin G (anti-SOST–IgG) have been recently studied in patients with ankylosing spondylitis (AS) as a putative marker of disease activity.Methods. SOST and anti-SOST-IgG serum levels were assayed in 125 patients with IBD, 85 with axial or peripheral SpA, and in control groups (patients with AS and rheumatoid arthritis, and healthy individuals). The diagnostic performance in discriminating the presence of SpA/IBD was assessed for both candidate biomarkers.Results. Patients affected by SpA/IBD with axial involvement displayed significantly lower levels of SOST and higher levels of anti-SOST-IgG compared to patients with only peripheral arthritis, IBD, and controls. Moreover, SOST and anti-SOST-IgG serum levels were inversely correlated and were associated with the duration of articular symptoms. Both biomarkers showed good accuracy in predicting the presence of axial SpA in patients with IBD.Conclusion. We demonstrated that in patients with IBD, SOST and anti-SOST-IgG might represent novel biomarkers to assess the presence of axial joint involvement. Moreover, the development of anti-SOST-IgG and the subsequent decrease of SOST serum levels could play a role in the pathogenesis of SpA/IBD. ER -